InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+58.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Sullivan Christopher Ryan, Directeur Comptable. Officer active across 1 company, notably Avalo Therapeutics, Inc.. In total, 9 disclosures have been logged. Split: 3 buys · 0 sell. Total volume traded: €4k. History available since 10 December 2021. The latest transaction was disclosed on 21 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations9 total
138 sharesCommon StockSEC:0001810417-26-000016:0
39,900 shares0Common StockSEC:0001810417-26-000014:0
24,200 sharesCommon StockSEC:0001810417-26-000004:0
8,241 shares@ US$13.890.030% mcap61.8% of flowCommon StockSEC:0001810417-26-000004:1
24,200 sharesCommon StockSEC:0001578563-25-000198:0
7,285 shares@ US$8.4635.5% of flowCommon StockSEC:0001578563-25-000198:1
511 shares@ US$3.421.0% of flowCommon StockSEC:0001628280-23-021962:0
Ideal exit: 5 Mar 2024 (T+270)
955 shares@ US$1.570.8% of flowCommon StockSEC:0001879785-21-000039
Ideal exit: 6 Sept 2022 (T+270)
955 shares@ US$1.570.0004% mcap50.0% of flowCommon StockSEC:0001879785-21-000039:0
Ideal exit: 6 Sept 2022 (T+270)
9 of 9 declarations
About Sullivan Christopher Ryan
Christopher Ryan Sullivan is the Chief Accounting Officer at Avalo Therapeutics, Inc. He oversees accounting operations and ensures financial compliance for the company. His role is crucial for maintaining financial transparency.
